No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: An investigation using cimetidine

Journal of Clinical Pharmacology

Volumn 51, Issue 4, 2011, Pages 594-602

  Böhmer, Gabriele M ^a   Gleiter, Christoph H ^a   Mörike, Klaus ^a   Nassr, Nassr ^b   Walz, Antje ^b   Lahu, Gezim ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Nycomed GmbH   (Germany)

Author keywords

Cimetidine; Drug drug interactions; Phase I study; Roflumilast; Roflumilast N oxide

Indexed keywords

CIMETIDINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; MYALGIA; NAUSEA; NORMAL HUMAN; PAIN; PHARMACOKINETICS; REPEATED DRUG DOSE; SHOCK; SINGLE DRUG DOSE; SPRAIN; STEADY STATE; TOOTH PAIN; UPPER ABDOMINAL PAIN; VOMITING;

ADULT; AMINOPYRIDINES; BENZAMIDES; CIMETIDINE; CROSS-OVER STUDIES; CYCLOPROPANES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 79953770692     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010368282     Document Type: Article

References (39)

1. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med. 2003;54:113-129. (Pubitemid 37386387)
2. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med. 2001;344:350-362. (Pubitemid 32107645)
3. Caramori G, Pandit A, Papi A. Is there a difference between chronic airway inflammation in chronic severe asthma and chronic obstructive pulmonary disease? Curr Opin Allergy Clin Immunol. 2005;5:77-83. (Pubitemid 40175500)
4. Guerra S. Overlap of asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2005;11:7-13. (Pubitemid 40189245)
5. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368:780-793. (Pubitemid 44279056)
6. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167-175. (Pubitemid 40091808)
7. Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med. 2005;11:129-134. (Pubitemid 40279919)
8. Vignola AM. PDE4 inhibitors in COPD: a more selective approach to treatment. Respir Med. 2004;98:495-503. (Pubitemid 38701852)
9. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62:1081-1087. (Pubitemid 350206202)
10. Engelstatter R, Wingertzahn M, Schmid-Wirlitsch C, et al. Roflumilast, an oral once-daily phosphodiesterase 4 (PDE4) inhibitor does not exhibit bronchodilator activity. Ann Allergy Asthma Immunol. 2005;94:169.
11. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154-161. (Pubitemid 47057851)
12. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685-694.
13. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695-703.
14. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366:563-571. (Pubitemid 41140331)
15. Nassr N, Huennemeyer A, Herzog R, et al. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Pharmacol. 2009;68:580-587.
16. von Richter O, Lahu G, Huennemeyer A, et al. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet. 2007;46:613-622. (Pubitemid 47025361)
17. Bethke TD, Bohmer GM, Hermann R, et al. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol. 2007;47:26-36. (Pubitemid 44973995)
18. Reid P. Roflumilast Altana Pharma. Curr Opin Investig Drugs. 2002;3:1165-1170.
19. Hermann R, Lahu G, Hauns B, et al. "Total PDE4 inhibitory activity": a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions. Eur Respir J. 2006;28:436s.
20. Bodemar G, Norlander B, Walan A. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet. 1981;6:306-315. (Pubitemid 12219235)
21. Brogden RN, Heel RC, Speight TM, Avery GS. Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs. 1978;15:93-131. (Pubitemid 8266264)
22. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists: relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet. 1991;20:218-236.
23. Richards DA. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. J Clin Gastroenterol. 1983;5(suppl 1):81-90. (Pubitemid 14214244)
24. Brimblecombe RW, Duncan WA, Durant GJ, et al. The pharmacology of cimetidine, a new histamine H2-receptor antagonist. Br J Pharmacol. 1975;53:435P-436P.
25. Prandota J, Smith IJ, Wilson JT. Dosage regimen of cimetidine reviewed: possible drug accumulation after multiple oral doses. Eur J Clin Pharmacol. 1988;34:539-542.
26. Pedersen PV, Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci. 1980;69:394-398. (Pubitemid 10079747)
27. Thomson Healthcare Inc. Micromedex® Healthcare Series, 131. 2007.
28. Furuta S, Kamada E, Suzuki T, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica. 2001;31:1-10. (Pubitemid 32337057)
29. Klotz U, Reimann I. Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol. 1980;18:517-520. (Pubitemid 11195841)
30. Klotz U, Reimann I. Effect of histamine H2-receptor antagonists on the hepatic elimination of drugs [in German]. Klin Wochenschr. 1983;61:625-632.
31. Knodell RG, Browne DG, Gwozdz GP, et al. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology. 1991;101:1680-1691.
32. Somogyi AA, Reinhard HA, Bochner F. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers. Eur J Clin Pharmacol. 1996;50:417-419. (Pubitemid 26228258)
33. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2006.
34. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-857.
35. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor. Drug Metab Dispos. 1999;27:1519-1522.
36. Loi CM, Parker BM, Cusack BJ, Vestal R. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br J Clin Pharmacol. 1993;36:195-200. (Pubitemid 23275334)
37. Renwick AB, Ball SE, Tredger JM, et al. Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica. 2002;32:849-862. (Pubitemid 35155520)
38. Lahu G, Huennemeyer A, von Richter O, et al. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2008;48:1339-1349.
39. Nassr N, Lahu G, Huennemeyer A, et al. Magnesium hydroxide/aluminum hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. J Clin Pharmacol. 2007;47:660-666. (Pubitemid 46632147)